SITUS JUDI MBL77 - AN OVERVIEW

Not all people with CLL demand therapy. Despite all the latest improvements, the iwCLL even now endorses watchful observation for people with asymptomatic disorder.86 This suggestion is predicated on not less than two randomized trials evaluating observation to possibly chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR).1